首页> 外文期刊>Anesthesia and Analgesia: Journal of the International Anesthesia Research Society >A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy.
【24h】

A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy.

机译:比较aprepitant和地塞米松的组合与ondansetron和地塞米松的组合对开颅手术患者预防恶心和呕吐的预防作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Postoperative nausea and vomiting (PONV) occur commonly after craniotomy. In patients receiving prophylaxis with ondansetron and dexamethasone, vomiting occurred in 45% of patients at 48 hours. In addition to causing patient discomfort, the physical act of vomiting may increase intracranial pressure or cerebral intravascular pressure, jeopardizing hemostasis and cerebral perfusion. Aprepitant is a neurokin-1 receptor antagonist with a long duration of action and no sedative side effect. In a large multicenter study in patients undergoing abdominal surgery, aprepitant was significantly more effective than was ondansetron in preventing vomiting at 24 and 48 hours postoperatively. We hypothesized that the combination of aprepitant with dexamethasone will decrease the incidence of postoperative vomiting when compared with the combination of ondansetron and dexamethasone in patients undergoing craniotomy under general anesthesia. METHODS: Patients scheduled to undergo craniotomy under general anesthesia were enrolled in this prospective, double-blind, randomized study. Patients were randomized to receive oral aprepitant 40 mg (or matching placebo) 1 to 3 hours before induction of anesthesia or ondansetron 4 mg IV (or placebo) within 30 minutes of the end of surgery. All patients received dexamethasone 10 mg after induction of anesthesia. The anesthetic technique was standardized. Data were collected at regular intervals by blinded personnel for 48 hours after surgery. Statistical analysis was performed using Wilcoxon's ranked sum test and chi(2) test. P < 0.05 was considered statistically significant. RESULTS: One hundred four patients completed the study. The cumulative incidence of vomiting at 48 hours was 16% in the aprepitant group and 38% in the ondansetron group (P = 0.0149). The incidence of vomiting was also decreased in the aprepitant group at 2 hours (6% vs. 21%, P = 0.0419) and 24 hours (14% vs. 36%, P = 0.0124). From 0 to 48 hours, there was no difference between the aprepitant and ondansetron groups in the incidence of nausea (69% vs. 60%), nausea scores, need for rescue antiemetics (65% vs. 60%), complete response (no PONV and no rescue, 22% vs. 36%), or patient satisfaction with the management of PONV. CONCLUSION: The combination of aprepitant and dexamethasone was more effective than was the combination of ondansetron and dexamethasone for prophylaxis against postoperative vomiting in adult patients undergoing craniotomy under general anesthesia. However, there was no difference between the groups in the incidence or severity of nausea, need for rescue antiemetics, or in complete response between the groups.
机译:背景:开颅手术后通常会发生术后恶心和呕吐(PONV)。在接受恩丹西酮和地塞米松预防的患者中,48小时时有45%的患者出现呕吐。除引起患者不适外,呕吐的身体行为可能会增加颅内压或脑血管内压,从而危害止血和脑灌注。 Aprepitant是一种Neurokin-1受体拮抗剂,具有长效作用且无镇静作用。在一项针对腹部手术患者的大型多中心研究中,阿瑞匹坦在预防术后24小时和48小时呕吐方面比恩丹西酮明显更有效。我们假设,在全身麻醉下进行开颅手术的患者中,与恩丹西酮和地塞米松联合使用时,阿瑞庇特与地塞米松联合使用将降低术后呕吐的发生率。方法:本项前瞻性,双盲,随机研究纳入了计划在全身麻醉下进行开颅手术的患者。在手术结束后的30分钟内,将患者随机分组,在麻醉诱导前1至3个小时接受口服阿瑞匹坦40 mg(或相匹配的安慰剂)或恩丹西酮4 mg IV(或安慰剂)。麻醉诱导后,所有患者均接受地塞米松10 mg。麻醉技术已标准化。盲人在手术后48小时定期收集数据。使用Wilcoxon的等级和检验和chi(2)检验进行统计分析。 P <0.05被认为具有统计学意义。结果:104名患者完成了研究。阿瑞吡坦组48小时呕吐的累积发生率为16%,恩丹西酮组为38%(P = 0.0149)。在阿瑞吡特组,在2小时(6%对21%,P = 0.0419)和24小时(14%对36%,P = 0.0124)时,呕吐的发生率也降低了。从0到48小时,aprepitant组和恩丹西酮组在恶心发生率(69%vs. 60%),恶心评分,急救止吐药的需要(65%vs. 60%),完全缓解(无)方面无差异。 PONV且无急救,分别为22%和36%),或者患者对PONV的管理感到满意。结论:在全身麻醉下开颅手术的成年患者中,aprepitant和地塞米松联合使用比恩丹西酮和地塞米松联合治疗更有效地预防术后呕吐。但是,两组之间在恶心的发生率或严重程度,是否需要紧急止吐药或两组之间的完全缓解方面没有差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号